Ambulatory Blood Pressure and Adherence Monitoring: Diagnosing Pseudoresistant Hypertension

Seminars in Nephrology

Volumn 34, Issue 5, 2014, Pages 498-505

  Burnier, Michel ^a   Wuerzner, Gregoire ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drug adherence; Hypertension therapy; Pseudohypertension; Renal denervation; Secondary hypertension

Indexed keywords

AMILORIDE; AMLODIPINE; BISOPROLOL; CHLORTALIDONE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; ANTIDIABETIC AGENT;

BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HUMAN; MEDICATION COMPLIANCE; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PSEUDORESISTANT HYPERTENSION; RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; CORONARY VASOSPASM; DRUG RESISTANCE; HYPERTENSION;

BLOOD PRESSURE MONITORING, AMBULATORY; CORONARY VASOSPASM; DIURETICS; DRUG RESISTANCE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE;

EID: 84918520446     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.08.003     Document Type: Review

References (58)

1. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25:1751-1762.
2. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311:507-520.
3. Joffres M., Falaschetti E., Gillespie C., Robitaille C., Loustalot F., Poulter N., et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013, 3:e003423.
4. Acelajado M.C., Pisoni R., Dudenbostel T., Dell'Italia L.J., Cartmill F., Zhang B., et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens 2012, 14:7-12.
5. Cushman W.C., Ford C.E., Cutler J.A., Margolis K.L., Davis B.R., Grimm R.H., et al. Success and predictors of BP control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393-404. for the ALLHAT Collaborative Research Group.
6. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
7. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
8. Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.D. Uncontrolled and apparent treatment resistant hypertension in the U.S. 1988-2008. Circulation 2011, 124:1046-1058.
9. de la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
10. Calhoun D.A., Booth J.N., Oparil S., Irvin M.R., Shimbo D., Lackland D.T., et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014, 63:451-458.
11. Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125:1635-1642.
12. Gupta A.K., Nasothimiou E.G., Chang C.L., Sever P.S., Dahlöf B., Poulter N.R. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011, 29:2004-2013. ASCOT Investigators.
13. O'Brien E., Parati G., Stergiou G. Ambulatory blood pressure measurement: what is the international consensus?. Hypertension 2013, 62:988-994.
14. Waeber B., Scherrer U., Petrillo A., Bidiville J., Nussberger J., Waeber G., et al. Are some hypertensive patients overtreated? A prospective study of ambulatory blood pressure recording. Lancet 1987, 2:732-734.
15. Krause T., Lovibond K., Caulfield M., McCormack T., Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011, 343:d4891. Guideline Development Group.
16. Bobrie G., Chatellier G., Genes N., Clerson P., Vaur L., Vaisse B., et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004, 291:1342-1349.
17. Pogue V., Rahman M., Lipkowitz M., Toto R., Miller E., Faulkner M., et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009, 53:20-27. African American Study of Kidney Disease and Hypertension Collaborative Research Group.
18. Yano Y., Bakris G.L. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens 2013, 7:244-252.
19. Franklin S.S., Thijs L., Li Y., et al. International Database on Ambulatory blood pressure in Relation to Cardiovascular Outcomes Investigators. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013, 61:964-971.
20. Masked hypertension in diabetes mellitus. Hypertension 2013, 61:931. Clinical implications.
21. Ríos M.T., Domínguez-Sardiña M., Ayala D.E., Gomara S., Sineiro E., Pousa L., et al. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 2013, 30:207-220.
22. De Nicola L., Gabbai F.B., Agarwal R., Chiodini P., Borrelli S., Bellizzi V., et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013, 61:2461-2467.
23. Burnier M., Wuerzner G., Struijker Boudier H., Urquhart J. Measuring, analyzing and managing drug adherence in resistant hypertension. Hypertension 2013, 62:218-225.
24. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012, 125:882-887.
25. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008, 336:1114-1117.
26. Shi L., Liu J., Koleva Y., Fonseca V., Kalsekar A., Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 2010, 28:1097-1107.
27. Hamilton G.A. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003, 2:219-228.
28. Burnier M., Schneider M.P., Chioléro A., Stubi C.L., Brunner H.R. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001, 19:335-341.
29. Daugherty S.L., Powers J.D., Magid D.J., Masoudi F.A., Margolis K.L., O'Connor P.J., et al. The association between medication adherence and treatment intensification with BP control in resistant hypertension. Hypertension 2012, 60:303-309.
30. Jung O., Gechter J.L., Wunder C., Paulke A., Bartel C., Geiger H., et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013, 31:766-774.
31. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:69-74.
32. Pimenta E., Gaddam K.K., Oparil S., Aban I., Husain S., Dell'Italia L.J., et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54:475-481.
33. Iftikhar I.H., Hays E.R., Iverson M.A., Magalang U.J., Maas A.K. Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med 2013, 9:165-174.
34. Martínez-García M.A., Capote F., Campos-Rodríguez F., Lloberes P., Díaz de Atauri M.J., Somoza M., et al. Spanish Sleep Network. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA 2013, 310:2407-2415.
35. Yakovlevitch M., Black H.R. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991, 151:1786-1792.
36. Setaro J.F., Black H.R. Refractory hypertension. N Engl J Med 1992, 327:543-547.
37. Egan B.M., Zhao Y., Li J., Brzezinski W.A., Todoran T.M., Brook R.D., et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013, 62:691-697.
38. Peterzan M.A., Hardy R., Chaturvedi N., Hughes A.D. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012, 59:1104-1109.
39. Roush G.C., Holford T.R., Guddati A.K. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012, 59:1110-1117.
40. Ernst M.E., Carter B.L., Goerdt C.J., Steffensmeier J.J., Phillips B.B., Zimmerman M.B., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
41. Na K.Y., Oh Y.K., Han J.S., Lee J.S., Earm J.H., Knepper M.A., et al. Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats. Am J Physiol Renal Physiol 2003, 284:F133-F143.
42. Nielsen J., Kwon T.H., Masilamani S., Beutler K., Hager H., Nielsen S., et al. Sodium transporter abundance profiling in kidney: effect of spironolactone. Am J Physiol Renal Physiol 2002, 283:F923-F933.
43. Knauf H., Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 1997, 29:367-372.
44. Bobrie G., Frank M., Azizi M., Peyrard S., Boutouyrie P., Chatellier G., et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012, 30:1656-1664.
45. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., Pimenta E., Aban I., Oparil S., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
46. Chapman N., Dobson J., Wilson S., Dahlöf B., Sever P.S., Wedel H., et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
47. Engbaek M., Hjerrild M., Hallas J., Jacobsen I.A. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010, 4:290-294.
48. Alvarez-Alvarez B., Abad-Cardiel M., Fernandez-Cruz A., Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010, 28:2329-2335.
49. Ouzan J., Perault C., Lincoff A.M., Carre E., Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
50. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
51. Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006, 19:750-755.
52. Lane D.A., Shah S., Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891-894.
53. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
54. Gaddam K., Pimenta E., Thomas S.J., Cofield S.S., Oparil S., Harding S.M., et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010, 24:532-537.
55. Václavík J., Sedlák R., Plachy M., Navrátil K., Plásek J., Jarkovsky J., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57:1069-1075.
56. Bakris G.L., Nadim M.K., Haller H., Lovett E.G., Schafer J.E., Bisognano J.D. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012, 6:152-158.
57. Mahfoud F., Ukena C., Schmieder R.E., Cremers B., Rump L.C., et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013, 128:132-140.
58. Persu A., Jin Y., Azizi M., Baelen M., Volz S., Elvan A., et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2013, 12:868-879.